Aldosterone Breakthrough During Angiotensin II Receptor Blockade in Hypertensive Patients With Diabetes Mellitus

American Journal of Hypertension

Volumn 20, Issue 12, 2007, Pages 1329-1333

  Yoneda, Takashi ^a   Takeda, Yoshiyu ^a   Usukura, Mikiya ^a   Oda, Nobushige ^a   Takata, Hiroyuki ^a   Yamamoto, Yasuhiro ^a   Karashima, Shigehiro ^a   Yamagishi, Masakaz ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

Aldosterone; angiotensin receptor blocker; diabetic nephropathy; hypertension

Indexed keywords

ALDOSTERONE; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; BIOCHEMICAL MARKER; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; DOXAZOSIN MESYLATE; RENIN; SPIRONOLACTONE; VALSARTAN;

ADD ON THERAPY; ADULT; AGED; ALBUMINURIA; ALDOSTERONE BLOOD LEVEL; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

AGED; ALBUMINURIA; ALDOSTERONE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BENZIMIDAZOLES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; TETRAZOLES; VALINE;

EID: 36349036058     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjhyper.2007.09.001     Document Type: Article

References (21)

1. Milliez P., Girerd X., Plouin P.-F., Blacher J., Safar M.E., and Mourad J.-J. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 45 (2005) 1243-1248
2. Takeda Y. Genetic alterations in patients with primary aldosteronism. Hypertens Res 24 (2001) 469-474
3. Pitt B., Zannad F., Remme W.J., Cody R., Castaigne A., Perez A., Palensky J., Wittes J., and Randomized Aldactone Evaluation Study. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341 (1999) 709-717
4. Rocha R., Chander P.N., Khanna K., Zuckerman A., and Stier Jr. C.T. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 31 (1998) 451-458
5. Takeda Y., Yoneda T., Demura M., Usukura I., and Mabuchi H. Calcineurin inhibition attenuates mineralocorticoid-induced cardiac hypertrophy. Circulation 105 (2002) 677-679
6. Sato A., and Saruta T. Aldosterone breakthrough during angiotensin-converting enzyme inhibitor therapy. Am J Hypertens 16 (2003) 781-788
7. McKelvie R.S., Yusuf S., Pericak D., Avezum A., Burns R.J., Probstfield J., Tsuyuki R.T., White M., Rouleau J., Latini R., Maggioni A., Young J., and Pogue J. Comparison of candesartan, enalapril, and their combination in congestive heart failure. Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study. Circulation 100 (1999) 1056-1064
8. Cohn J.N., Anand I.S., Latini R., Masson S., Chiang T.-T., and Glazer R. Sustained reduction of aldosterone in response to angiotensin receptor blocker valsartan in patients with chronic heart failure. Results from the Valsartan Heart Failure Trial. Circulation 108 (2003) 1306-1309
9. Sato A., Hayashi K., Naruse M., and Saruta T. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 41 (2003) 64-68
10. Horita Y., Taura K., Taguchi T., Furusu A., and Kohno S. Aldosterone breakthrough during therapy with angiotensin-converting enzyme inhibitors and angiotensin II receptors in proteinuric patients with immunoglobulin A nephropathy. Nephrology 11 (2006) 462-466
11. Sato A., and Saruta T. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy. J Int Med Res 29 (2001) 13-21
12. Takeda Y., Miyamori I., Yoneda T., Furukawa K., Hatakeyama H., Inab S., Ito Y., Takeda R., and Mabuchi H. Effect of adrenocorticotropin stimulation on the synthesis of 19-noraldosterone in man. J Clin Endocrinol Metab 81 (1996) 1852-1855
13. Gomez-Sanchez C.E., Clone J.N., Estep H.L., and Watlington C.O. Effect of chronic adrenocorticotropin stimulation on the excretion of 18-hydroxycortisol and 18-oxocortisol. J Clin Endocrinol Metab 67 (1988) 322-326
14. Naruse M., Tanabe A., Sato A., Takagi S., Tsuchiya K., Imaki T., and Takano K. Aldosterone breakthrough during angiotensin II receptor antagonist therapy in stroke-prone spontaneously hypertensive rats. Hypertension 40 (2002) 28-33
15. Takeda Y., Usukura M., Yoneda T., Oda N., Ito Y., and Mabuchi H. The expression of messenger RNA for ADP-ribosyl cyclase in aldosterone-producing adenomas. Clin Endocrinol (Oxf) 62 (2005) 504-508
16. Epstein M., Williams G.H., Weinberger M., Lewin A., Krause S., Mukherjee R., Patni R., and Beckman B. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with Type 2 diabetes. Clin J Am Soc Nephrol 1 (2006) 940-951
17. Chrysostomou A., and Becker G. Spironolactone in addition to ACE inhibitors to reduce proteinuria in patients with chronic renal disease. N Engl J Med 345 (2001) 925-926
18. Epstein M. Aldosterone blockade: an emerging strategy for abrogating progressive renal disease. Am J Med 119 (2006) 912-919
19. Rocha R., Chander P.N., Zuckerman A., and Stir Jr. C.T. Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension 33 (1999) 232-237
20. Blasi E.R., Rocha R., Rudolph A.E., Blomme E.A., Polly M.L., and McMahon E.G. Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int 63 (2003) 1791-1800
21. Schepkens H., Vanholder R., Billiouw J.M., and Lameire N. Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases. Am J Med 116 (2001) 438-441